An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in CAH at ENDO 2026 On June 14, Crinetics Pharmaceuticals, Inc. presented data from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral […]
